Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galapagos NV ADR (NQ: GLPG )

26.92 +0.21 (+0.79%)
Streaming Delayed Price Updated: 11:18 AM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30,914
Open 26.92
Bid (Size) 26.91 (1)
Ask (Size) 26.93 (2)
Prev. Close 26.71
Today's Range 26.71 - 26.95
52wk Range 24.16 - 42.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T... 
Via Benzinga

Performance

YTD
-34.88%
-34.88%
1 Month
-11.10%
-11.10%
3 Month
+8.33%
+8.33%
6 Month
-8.65%
-8.65%
1 Year
-29.33%
-29.33%

More News

Read More
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Via Investor's Business Daily
Exposures Product Safety
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
8 Analysts Have This to Say About Galapagos
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
Via Benzinga
Earnings Outlook For Galapagos
Via Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Via Benzinga
Exposures Product Safety
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Via Newsfile
Earnings Preview For Galapagos
Via Benzinga
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
Via Benzinga
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
From Frontier Medicines
Via GlobeNewswire
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
Via Benzinga
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
Via Benzinga
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
Via Benzinga
Why Galapagos Stock Is Falling Today
Via Benzinga
Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
Via Benzinga
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.